Expanded IMPACT For GSK Respiratory Business From New Trelegy Data
Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta and Anoro Ellipta support the product's ability to reduce exacerbations in more severe COPD. However, the benefit of IMPACT in expanding GSK's respiratory sales may be limited given pricing pressures and the make-up of GSK's current portfolio.
You may also be interested in...
The latest US drug development news and highlights from our Performance Tracker.
Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.
GSK's triple COPD combo needs Phase III trial using comparators with same active ingredients and applying factorial design, BI contends in citizen petition to US FDA.